Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study
2024
Correction on Pembrolizumab and Radiotherapy Study
publication
Author Information
Author(s): De Jaeghere Emiel A., Tuyaerts Sandra, Van Nufel An M. T., Belmans Ann, Bogaerts Kris, Baiden-Amissah Regina, Lippens Lien, Vuylsteke Peter, Henry Stéphanie, Trinh Xuan Bich, van Dam Peter A., Aspeslagh Sandrine, De Caluwé Alex, Naert Eline, Lambrechts Diether, Hendrix An, De Wever Olivier, Van de Vijver Koen K., Amant Frédéric, Vandecasteele Katrien, Denys Hannelore G.
Primary Institution: Ghent University Hospital
Conclusion
The correction clarifies a typo regarding regulatory approval for Cemiplimab in the EU instead of the USA.
Takeaway
This article fixed a small mistake about where a cancer drug was approved, changing it from the USA to the EU.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website